AstraZeneca PLC ADR AZN
News
Cellectis Reports Financial Results for First Quarter 2024
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024
AstraZeneca kicks off 'new era of growth' with aim to hit $80 billion of sales by 2030
AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
AstraZeneca Plans $1.5 Billion Manufacturing Facility in Singapore
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit — Update
France Secures Billions at Foreign Investment Summit
AstraZeneca withdraws COVID-19 vaccine
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
Astrazeneca on Track for Record High Close — Data Talk
Astrazeneca on Track for Record High Close — Data Talk
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow